Pax8: A marker for carcinoma of Müllerian origin in serous effusions

Diagnostic Cytopathology

Volumn 39, Issue 8, 2011, Pages 562-566

  Tong, Guo Xia ^a   Devaraj, Kalpana ^a   Hamele Bena, Diane ^a   Yu, Woojin M ^a   Turk, Andrew ^a   Chen, Xiaowei ^a   Wright, Jason D ^a   Greenebaum, Ellen ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

carcinomas of M llerian origin; endometrial carcinoma; papillary serous carcinoma of the peritoneum; PAX8; serous effusions

Indexed keywords

TRANSCRIPTION FACTOR PAX8; TUMOR MARKER;

ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MIXED MULLERIAN TUMOR; OVARY CARCINOMA; OVARY METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STROMA CELL; TISSUE MICROARRAY; UTERINE CERVIX; UTERUS; UTERUS CANCER; UTERUS LEIOMYOSARCOMA;

EID: 79957990905     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21426     Document Type: Article

References (38)

1. Davidson B,. Malignant effusions: From diagnosis to biology. Diagn Cytopathol 2004; 31: 246-254. (Pubitemid 39314820)
2. Bedrossian CW,. Special stains, the old and the new: The impact of immunocytochemistry in effusion cytology. Diagn Cytopathol 1998; 18: 141-149. (Pubitemid 28087017)
3. Zhu W, Michael CW,. WT1, monoclonal CEA. TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007; 35: 370-375. (Pubitemid 46835030)
4. Lee BH, Hecht JL, Pinkus JL, Pinkus GS,. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 2002; 117: 745-750. (Pubitemid 34457009)
5. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009; 33: 14-21.
6. Lang D, Powell SK, Plummer RS, Young KP, Ruggeri BA,. PAX genes: Roles in development, pathophysiology, and cancer. Biochem Pharmacol 2007; 73: 1-14. (Pubitemid 44868976)
7. Mittag J, Winterhager E, Bauer K, Grummer R,. Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 2007; 148: 719-725. (Pubitemid 46143173)
8. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol 2007; 104: 331-337. (Pubitemid 46135661)
9. Nonaka D, Chiriboga L, Soslow RA,. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 2008; 32: 1566-1571.
10. Tong GX, Weeden EM, Hamele-Bena D, et al. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: Evidence of related histogenesis? Am J Surg Pathol 2008; 32: 1380-1387.
11. Bedrossian CW,. Diagnostic problems in serous effusions. Diagn Cytopathol 1998; 19: 131-137. (Pubitemid 28357785)
12. Barberis MC, Faleri M, Veronese S, Casadio C, Viale G,. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 1997; 41: 1757-1761. (Pubitemid 27516306)
13. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H,. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005; 32: 151-155. (Pubitemid 40256264)
14. Pomjanski N, Grote HJ, Doganay P, Schmiemann V, Buckstegge B, Bocking A,. Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Diagn Cytopathol 2005; 33: 309-315. (Pubitemid 41598050)
15. Mizutani Y, Nakajima T, Morinaga S, et al. Immunohistochemical localization of pulmonary surfactant apoproteins in various lung tumors. Special reference to nonmucus producing lung adenocarcinomas. Cancer 1988; 61: 532-537. (Pubitemid 18039368)
16. Burt A, Goudie RB,. Diagnosis of primary thyroid carcinoma by immunohistological demonstration of thyroglobulin. Histopathology 1979; 3: 279-286. (Pubitemid 9250758)
17. Olsburgh J, Harnden P, Weeks R, et al. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol 2003; 199: 41-49. (Pubitemid 36054728)
18. Brown RW, Campagna LB, Dunn JK, Cagle PT,. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997; 107: 12-19. (Pubitemid 27104630)
19. Rossi G, Cavazza A, Sturm N, et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: A clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol 2003; 27: 311-324. (Pubitemid 36245796)
20. Dubeau L,. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: Does the emperor have no clothes? Gynecol Oncol 1999; 72: 437-442. (Pubitemid 29118208)
21. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: A new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19: 3-9. (Pubitemid 46095865)
22. Miralles C, Orea M, Espana P, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003; 10: 150-154. (Pubitemid 40485935)
23. Al-Hussaini M, Stockman A, Foster H, McCluggage WG,. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004; 44: 109-115. (Pubitemid 38296970)
24. Masse J, Watrin T, Laurent A, Deschamps S, Guerrier D, Pellerin I,. The developing female genital tract: From genetics to epigenetics. Int J Dev Biol 2009; 53: 411-424.
25. Blake JA, Thomas M, Thompson JA, White R, Ziman M,. Perplexing Pax: From puzzle to paradigm. Dev Dyn 2008; 237: 2791-2803.
26. Vainio S, Heikkila M, Kispert A, Chin N, McMahon AP,. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999; 397: 405-409.
27. Bloss JD, Brady MF, Liao SY, Rocereto T, Partridge EE, Clarke-Pearson DL,. Extraovarian peritoneal serous papillary carcinoma: A phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma - A Gynecologic Oncology Group Study. Gynecol Oncol 2003; 89: 148-154. (Pubitemid 36403661)
28. Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: A case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993; 50: 347-351. (Pubitemid 23299731)
29. Casey MJ, Bewtra C,. Peritoneal carcinoma in women with genetic susceptibility: Implications for Jewish populations. Fam Cancer 2004; 3: 265-281. (Pubitemid 39491744)
30. Eltabbakh GH, Piver MS, Natarajan N, Mettlin CJ,. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol 1998; 91: 254-259. (Pubitemid 28074157)
31. Chu P, Wu E, Weiss LM,. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol 2000; 13: 962-972.
32. Pereira TC, Saad RS, Liu Y, Silverman JF,. The diagnosis of malignancy in effusion cytology: A pattern recognition approach. Adv Anat Pathol 2006; 13: 174-184. (Pubitemid 44341653)
33. Plachov D, Chowdhury K, Walther C, Simon D, Guenet JL, Gruss P,. Pax8, a murine paired box gene expressed in the developing excretory system and thyroid gland. Development 1990; 110: 643-651. (Pubitemid 20330539)
34. Poleev A, Fickenscher H, Mundlos S, et al. PAX8, a human paired box gene: Isolation and expression in developing thyroid, kidney and Wilms' tumors. Development 1992; 116: 611-623.
35. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G,. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 1994; 54: 4744-4749. (Pubitemid 24276506)
36. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: An immunohistochemical study. Mod Pathol 2009; 22: 1218-1227.
37. Muratovska A, Zhou C, He S, Goodyer P, Eccles MR,. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 2003; 22: 7989-7997. (Pubitemid 37179944)
38. Pellizzari L, Puppin C, Mariuzzi L, et al. PAX8 expression in human bladder cancer. Oncol Rep 2006; 16: 1015-1020.